Palonosetron: profile and news

AP Pharma Reports 2006 First Quarter Results; Phase 3 Clinical ... May 10, 2006
...each; two arms will be treated with APF530, high and low dose form and a third arm will be treated with the currently approved dose of palonosetron (brand name ... - Genetic Engineering News,

AbelsonTaylor Announces Four New Appointments May 11, 2006
Laura Dodd, newly hired senior copywriter, will manage projects for Aloxi (palonosetron HCL injection), a drug for treating adverse effects of chemotherapy ... - PharmaLive.com (press release),

MGI PHARMA to Present at the 2006 Bank of America Health Care ... May 11, 2006
MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... - PharmaLive.com (press release),

US FDA Approves Dacogen(TM) (Decitabine) For Injection May 3, 2006
MGI PHARMA markets Aloxi® (palonosetron hydrochloride) Injection and Gliadel® Wafer (polifeprosan 20 with carmustine implant) in the United States, and ... - Yahoo! News (press release)

US FDA Approves Dacogen(TM) (Decitabine) for Injection; Dacogen(TM ... May 3, 2006
MGI PHARMAmarkets Aloxi(R) (palonosetron hydrochloride) Injection and Gliadel(R)Wafer (polifeprosan 20 with carmustine implant) in the United States,and ... - Finanzen.net,

MGI PHARMA Announces Publication of Phase 3 Data for Dacogen ... Apr 18, 2006
MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... - PharmaLive.com (press release),

MGI PHARMA Reports First Quarter 2006 Financial Results; First ... Apr 19, 2006
During the first quarter of 2006, US sales of Aloxi(R) (palonosetron hydrochloride) Injection totaled $63.3 million compared to $57.2 million in the first ... - Business Wire (press release),

Other information

Indication
For the treatment of aausea and vomiting associated with cancer chemotherapy

Pharmacology
Palonosetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Palonosetron is a highly specific and selective serotonin 5-HT₃ receptor antagonist, not shown to have activity at other known serotonin receptors and with low affinity for dopamine receptors.

Mechanism Of Action
Palonosetron is a selective serotonin 5-HT₃ receptor antagonist. The serotonin 5-HT₃ receptors are located on the nerve terminals of the vagus in the periphery and centrally in the chemoreceptor trigger zone of the area postrema. It is thought that chemotherapeutic agents produce nausea and vomiting by releasing serotonin from the enterochromaffin cells of the small intestine, and that the released serotonin then activates 5-HT₃ receptors located on vagal efferents to initiate the vomiting reflex. Therefore Palonosetron works by blocking the reception of serotonin at these 5-HT₃ receptors.

Drug Category
Antiemetics; ATC:A04AA

Brand Names/Synonyms
Aloxi; Onicit; Palonosetron; Raloxifene

Dosage Forms
Not Available

Absorption
Not Available

Interactions
-->Interactions for Palonosetron:

Palonosetron is eliminated from the body through both renal excretion and metabolic pathways. Therefore, the potential for clinically significant drug interactions with palonosetron appears to be low.

Chemical IUPAC Name
Not Available

Chemical Formula
C19H24N2O

Half Life
Approximately 40 hours

Drug Type
Approved Drug

# Accession No
APRD00351

CAS Registry Number
119904-90-4